SOPHiA GENETICS (SOPH) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.20

Estimate

-$0.22

Surprise

+10.9%

Score today

5.7/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

SOPHiA GENETICS (SOPH) reported a narrower loss than forecast — diluted EPS of -$0.20 against the -$0.22 estimate (a 10.9% beat on a still-unprofitable quarter).

TrendMatrix currently rates SOPH Sell at 5.7/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's +10.9% surprise compares with a +11.9% four-quarter average. Next scheduled report: 2026-11-03.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$7.97

Price target

$8.29

Stop

$7.42

Upside to target

+4.0%

Reward-to-risk

0.3:1

Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Health Information Services

Market cap

$677.6M

P/E (fwd)

-15.9

52-week range

$3.15–$8.98

Off 52-week high

11.2%

RSI (14)

41

Volume vs avg

2.16×

Score today

5.7/10